News

Headquartered in Tampa, Florida, Biovest International, in collaboration with the National Cancer Institute, has developed a patient-specific, cancer vaccine, BiovaxID, with three clinical trials completed, including a Phase

The grants, which target therapeutic discovery projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent or treat

NitroMist is NovaDel’s oral spray formulation of nitroglycerin, which has been approved by the FDA for acute relief of an attack of angina pectoris, or acute prophylaxis of

Emergent posted a net income of $13.12m for the third quarter 2010, or $0.41 per diluted share, compared to net loss of $3.95m, or $0.03 per diluted share,

Amylin has posted a net loss of $50.73m for the third quarter 2010, or $0.35 loss per diluted share, compared to net loss of $26.66m, or $0.19 loss

Watson has posted a net income of $25.7m for the third quarter 2010, or $0.21 per diluted share, compared to net income of $63m, or $0.55 per diluted

In the trial, people participated lived a median of 6.2 months without their disease getting worse (median progression-free survival or PFS). Almost 52% of patients in the trial

In addition to the technical and business advisory services, the funding will be used to conduct studies and determine efficacy, selectivity and pharmacokinetics properties for the development of

Cymbalta has been established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis. Cymbalta, which has been shown to reduce chronic low